With current drug therapies, most people diagnosed with chronic phase chronic myeloid leukemia (CML) can expect to live good-quality lives.
Doctors have made much headway over the past decade in treating CML. Since the Food and Drug Administration's (FDA's) approval in 2001 of the tyrosine kinase inhibitor (TKI) drug imatinib mesylate (Gleevec®), most new cases of CML have been brought under control so that patients suffer few or no ill effects from the disease. Since then, the FDA has approved two other TKI drugs, nilotinib (Tasigna®) and dasatinib (Sprycel®), for initial therapy. If patients become drug resistant or intolerant or have a loss of response to one TKI, another TKI can be used for second-line treatment.
Your treatment and treatment goals depend on your CML phase: